PT-141 and Melanotan II are both melanocortin receptor agonists, which is why the two are often mentioned together. The most important thing to say up front is that they are not on equal footing: PT-141 (bremelanotide) is FDA-approved for a narrow indication, while Melanotan II is unapproved and carries documented risks. This comparison is about that distinction, framed cautiously.
Reviewed for accuracy · Last reviewed July 7, 2026The clearest difference is regulatory. PT-141 (bremelanotide) is genuinely FDA-approved as Vyleesi (2019), but only for acquired, generalized hypoactive sexual desire disorder in premenopausal women, given as a 1.75 mg as-needed subcutaneous injection. Use outside that group is off-label. Melanotan II is not approved by any regulator, has no validated dose, and authorities in the US, UK, and elsewhere have warned against it.
Mechanistically, PT-141 is more MC4R-focused, whereas Melanotan II activates melanocortin receptors non-selectively, which is why it affects pigmentation, appetite, sexual function, and cardiovascular tone at once. Both can cause nausea and flushing, and both can transiently affect blood pressure. Melanotan II carries additional documented concerns: priapism (a urological emergency), darkening of existing moles, eruption of new atypical moles, and case reports of melanoma in users, though case reports cannot establish causation on their own.
The honest reading is that these are not interchangeable. PT-141 has a label, trial data, and a defined regimen; Melanotan II is an unapproved gray-market product whose contents and dose are not guaranteed. Which, if either, is appropriate is a medical decision, and any new or changing mole after melanocortin use warrants a dermatology review.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.